Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

GSK's severe asthma therapy Nucala could find ... which still has several years of patent life left before it could face biosimilar competition. The lung disease affects more than 300 million ...

Review the table below to see how GSK plc stock stands up against its competitors. Click into any of the below tickers to see their stock grades for value, momentum, quality and EPS revisions. GSK plc ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

By enhancing DEI strategies, UK firms can set themselves apart, fostering inclusivity that drives growth – Reshma Sheikh explains As major US firms like Harley Davidson, Brown-Forman and Molson Coors ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and ...